Type 1 Diabetes

## What Is Type 1 Diabetes?

Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease defined by the immune-mediated destruction of insulin-secreting pancreatic beta cells, culminating in near-total or absolute insulin deficiency. Unlike type 2 diabetes, which is driven primarily by peripheral insulin resistance and relative insulin insufficiency, T1DM demands lifelong exogenous insulin replacement for metabolic survival. Without insulin, the body cannot facilitate cellular glucose uptake, and a cascade of metabolic derangements ensues that, left untreated, proves fatal within days to weeks.

The condition accounts for approximately 5 to 10 percent of all diabetes cases globally but carries outsized clinical and economic significance because it predominantly affects children, adolescents, and young adults during critical developmental periods. As of 2021, an estimated 8.4 million people worldwide live with T1DM, with projections suggesting this figure could reach 13.5 to 17.4 million by 2040. The United States reports more than 1.6 million individuals with the diagnosis, and the incidence rate continues to climb by roughly 2 to 3 percent annually in many high-income nations, a trend that remains incompletely explained.

Incidence follows a bimodal pattern, with the first peak occurring in early childhood between ages 4 and 6, and a second, larger peak emerging during puberty between ages 10 and 14. Hormonal changes during adolescence are believed to contribute to increased immune dysregulation and beta cell stress during this period. Notably, T1DM can and does develop in adults, where it may be misdiagnosed as type 2 diabetes due to its more gradual clinical presentation.

Geographic variation in incidence is striking. Finland and Sardinia report the world's highest incidence rates, exceeding 60 cases per 100,000 children per year, while parts of Asia and Latin America report rates below 1 per 100,000. These geographic differences implicate both genetic founder effects and environmental exposures in disease pathogenesis.

The public health impact of T1DM is profound. The disease imposes enormous demands on healthcare systems, requiring continuous medical supervision, expensive technologies, and intensive patient self-management. It reduces life expectancy by an estimated 11 to 13 years compared to the general population, primarily through cardiovascular and renal complications. The psychological burden is equally significant, with high rates of diabetes distress, depression, and anxiety reported among patients and their families, highlighting the need for comprehensive, patient-centered care models that address both biomedical and psychosocial dimensions of the disease.

## Symptoms and Clinical Presentation

The classic symptomatic presentation of type 1 diabetes reflects the physiological consequences of absolute insulin deficiency and resulting hyperglycemia. The hallmark triad of symptoms — polydipsia, polyuria, and polyphagia — arises from the body's inability to use glucose as an energy source and the compensatory mechanisms that attempt to address this metabolic failure.

Polydipsia, or excessive thirst, develops because elevated blood glucose creates an osmotic gradient that draws water from cells into the bloodstream and increases plasma osmolality, triggering the thirst center in the hypothalamus. Polyuria, or frequent and large-volume urination, results from osmotic diuresis: when blood glucose exceeds the renal threshold of approximately 180 mg/dL, glucose spills into the urine and draws water along with it, producing large volumes of dilute, glucose-rich urine. The resultant fluid loss further exacerbates thirst, creating a cycle of increasing dehydration.

Polyphagia, or excessive hunger, paradoxically accompanies hyperglycemia because insulin deficiency prevents glucose from entering cells, depriving tissues of their primary energy substrate. The hypothalamic hunger centers respond to this perceived cellular starvation by signaling increased food intake, even as blood glucose concentrations remain pathologically elevated.

Unintended weight loss is a prominent and often dramatic feature of new-onset T1DM, particularly in children. The body, unable to utilize glucose, mobilizes fat and protein stores for energy through lipolysis and gluconeogenesis. Patients may lose several kilograms over weeks, sometimes interpreted initially as growth-related changes or normal variation before the diagnosis is established.

Fatigue and generalized weakness result from the combination of cellular energy deprivation, dehydration, and the metabolic stress of gluconeogenesis and lipolysis. Blurred vision is common and reflects osmotic changes in the crystalline lens of the eye as glucose and its metabolites alter lens hydration and refractive index. Importantly, this type of visual blurring is typically transient and reverses with glycemic normalization, in contrast to the vision loss caused by long-standing diabetic retinopathy.

In a substantial proportion of children — estimates range from 25 to 40 percent in high-income countries and considerably higher in low-income settings — T1DM presents at the time of its first diagnosis as diabetic ketoacidosis (DKA), a life-threatening metabolic emergency. DKA occurs when insulin deficiency promotes unrestrained lipolysis and hepatic ketogenesis, leading to the accumulation of acidic ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) in the blood. Clinical features of DKA include nausea and vomiting, diffuse abdominal pain, Kussmaul respiration (deep and rapid breathing that compensates for metabolic acidosis), a characteristic fruity or acetone-like smell on the breath, and, in severe cases, altered consciousness and coma.

The rapidity of symptomatic onset can vary considerably. In very young children, the prodrome may be compressed into days, while in adolescents and adults, symptoms may evolve over weeks. Clinicians must maintain a high index of suspicion and avoid anchoring to alternative diagnoses such as gastroenteritis or influenza when the clinical picture is consistent with new-onset diabetes.

## Causes and Pathophysiology

Type 1 diabetes results from a complex interplay of genetic susceptibility, immune dysregulation, and environmental triggering factors that collectively lead to the autoimmune destruction of pancreatic beta cells. Understanding this pathophysiology is essential for appreciating current treatment strategies and future disease-modifying therapies.

The autoimmune process is orchestrated primarily by autoreactive CD4+ and CD8+ T lymphocytes that infiltrate the islets of Langerhans in a process termed insulitis. These T cells mistakenly recognize beta cell antigens as foreign and mount a destructive cellular immune response. Key autoantigens targeted include glutamic acid decarboxylase 65 (GAD65), insulin and proinsulin, islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8). The immune attack is gradual; beta cell mass declines over months to years before insulin deficiency becomes clinically apparent. By the time of clinical diagnosis, it is estimated that 70 to 90 percent of beta cell mass has already been lost.

Autoantibodies directed against these islet antigens serve as biomarkers of the autoimmune process and can be detected years before the onset of clinical symptoms. Their presence defines the pre-symptomatic stages of the disease: stage 1 involves multiple positive autoantibodies with normal glucose levels, stage 2 adds dysglycemia without overt symptoms, and stage 3 is symptomatic T1DM. This staging framework, established by the American Diabetes Association and Endocrine Society, has enabled the development of screening programs for at-risk individuals.

Genetic factors account for approximately 50 percent of the susceptibility to T1DM. The strongest genetic associations are with the human leukocyte antigen (HLA) complex, particularly class II alleles at the HLA-DQ and HLA-DR loci. The HLA-DR3-DQ2 and HLA-DR4-DQ8 haplotypes confer the greatest risk, while specific HLA-DR2 haplotypes are protective. Beyond HLA, genome-wide association studies (GWAS) have identified over 60 additional susceptibility loci, including PTPN22, INS, IL2RA, CTLA4, and IFIH1, many of which regulate immune tolerance mechanisms.

Environmental factors are required to trigger the disease in genetically susceptible individuals, given that the concordance rate for T1DM in identical twins is only 30 to 50 percent. Proposed environmental triggers include enteric viral infections — particularly coxsackievirus B and other enterovirus B species — which may induce molecular mimicry (cross-reactivity between viral and beta cell antigens), direct beta cell cytotoxicity, or bystander immune activation. Other implicated factors include early dietary exposures (early introduction of cow's milk proteins or cereal gluten during infancy), reduced gut microbiome diversity, vitamin D deficiency, and perinatal factors such as mode of delivery and antibiotic use in early life. The hygiene hypothesis posits that reduced early-life microbial exposure impairs the normal maturation of immune regulatory mechanisms, predisposing to autoimmune disease.

## Risk Factors

Risk factors for type 1 diabetes encompass both heritable and environmental dimensions, reflecting the disease's multifactorial etiology. Identifying individuals at elevated risk is increasingly important given the availability of autoantibody screening programs and emerging disease-modifying therapies.

Family history is one of the most robust clinical risk factors. The risk of developing T1DM is approximately 5 percent for offspring of an affected mother, 7 to 10 percent for offspring of an affected father, and 10 to 15 percent for siblings of an affected individual. This risk rises to 30 to 50 percent among identical twins, confirming a strong genetic component while also underscoring the critical role of non-genetic factors in disease expression.

HLA genotype is the dominant genetic determinant of risk. Individuals carrying the HLA-DR3/DR4-DQ8 compound heterozygous genotype face a lifetime risk approaching 30 percent, compared to roughly 0.4 percent in the general population. Genetic testing for HLA susceptibility alleles is increasingly used in research settings and newborn screening programs to identify at-risk infants.

The presence of islet autoantibodies dramatically stratifies risk. A child with a single autoantibody positive has a 15 to 25 percent lifetime risk of progression to clinical T1DM; those with two or more autoantibodies face a 50 to 80 percent lifetime risk, and risk approaches near-certainty with three or more autoantibodies combined with dysglycemia. TrialNet and other research consortia have leveraged this knowledge to enroll high-risk relatives into prevention trials.

Geographic and ethnic factors influence risk in ways that remain partially understood. Northern European ancestry, particularly Finnish and Swedish, confers the highest population-level risk. Non-Hispanic white individuals in North America also carry higher rates than Black, Hispanic, or Asian populations, though T1DM occurs across all ethnic groups. Higher socioeconomic status and the so-called Western lifestyle — characterized by reduced childhood infections, antibiotic use, urban living, and high-calorie diets — may paradoxically increase risk through immune system effects.

Other autoimmune conditions represent a clinically important risk factor. Approximately 25 to 30 percent of individuals with T1DM carry additional autoimmune conditions, most commonly autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease), celiac disease, and Addison's disease. The co-occurrence of multiple autoimmune conditions in the same individual reflects shared genetic pathways of immune regulation and is sometimes referred to as autoimmune polyendocrine syndrome.

## Diagnosis

The diagnosis of type 1 diabetes integrates clinical presentation, biochemical confirmation of hyperglycemia, assessment of insulin deficiency, and immunological markers of autoimmunity. Early and accurate diagnosis is critical to prevent life-threatening DKA and to initiate appropriate insulin therapy promptly.

According to the 2024 American Diabetes Association Standards of Care, the biochemical diagnosis of diabetes mellitus (regardless of type) is established by any one of the following criteria: a fasting plasma glucose of 126 mg/dL (7.0 mmol/L) or higher on two occasions; a two-hour plasma glucose of 200 mg/dL (11.1 mmol/L) or higher during a 75-gram oral glucose tolerance test; a hemoglobin A1c (HbA1c) of 6.5 percent or higher confirmed on repeat testing; or a random plasma glucose of 200 mg/dL or higher in a patient with classic hyperglycemic symptoms. In the presence of unambiguous symptomatic hyperglycemia or DKA, a single confirmatory test is sufficient.

Differentiating T1DM from other forms of diabetes, particularly T2DM and monogenic diabetes (MODY), requires additional investigations. Islet autoantibody testing is central to this process. The four major autoantibodies measured clinically are GADA (glutamic acid decarboxylase antibody), IA-2A (islet antigen-2 antibody), IAA (insulin autoantibody, most informative in young children prior to insulin exposure), and ZnT8A (zinc transporter 8 antibody). The presence of at least one autoantibody has a sensitivity of approximately 96 percent for T1DM at diagnosis, and testing for all four increases sensitivity further. False negatives are rare but can occur, particularly in adults with slowly progressive disease.

C-peptide measurement reflects endogenous insulin secretory capacity, since C-peptide is co-secreted with insulin in equimolar quantities from beta cells. Very low or undetectable C-peptide levels (below 0.2 nmol/L in the fasted state or below 0.6 nmol/L after a stimulated test) are characteristic of T1DM and indicate near-complete beta cell loss. Preserved C-peptide levels should prompt reconsideration of the diagnosis toward LADA, T2DM, or MODY.

When DKA is suspected or confirmed at presentation, urgent evaluation includes serum ketones or beta-hydroxybutyrate, arterial or venous blood gas, serum electrolytes (particularly potassium and bicarbonate), a complete metabolic panel, and urinalysis. Severity of DKA is classified as mild, moderate, or severe based on degree of acidosis (pH and bicarbonate), mental status, and anion gap.

Molecular genetic testing for HLA and non-HLA susceptibility alleles is performed in research and high-risk screening contexts, such as newborn screening programs and TrialNet-style cohort studies. HLA genotyping is not routinely required for clinical diagnosis but is increasingly integrated into precision medicine approaches for risk stratification and prediction of therapeutic response.

Differential diagnosis includes type 2 diabetes (distinguished by obesity, acanthosis nigricans, preserved C-peptide, and negative autoantibodies), MODY variants (distinguished by family history, specific gene mutations, preserved beta cell function, and negative autoantibodies), and secondary causes of diabetes including cystic fibrosis-related diabetes, pancreatogenic diabetes, and steroid-induced hyperglycemia.

## Treatment

The treatment of type 1 diabetes is grounded in insulin replacement that as closely as possible replicates the physiological insulin secretion profile of healthy pancreatic beta cells. This requires delivery of both a continuous low-level background (basal) insulin and discrete meal-time (bolus) insulin doses calibrated to carbohydrate intake, pre-meal glucose, and anticipated physical activity.

The basal-bolus insulin regimen using multiple daily injections (MDI) remains a cornerstone of T1DM management. Basal coverage is provided by long-acting insulin analogs such as insulin glargine U-100 or U-300, insulin degludec, or insulin detemir. These formulations have prolonged, relatively flat pharmacodynamic profiles that provide consistent background insulin suppression of hepatic glucose production over 24 hours. Meal-time bolus coverage uses rapid-acting analogs including insulin aspart, lispro, or glulisine, which have onset of action within 5 to 15 minutes, peak activity around 1 hour, and duration of 3 to 4 hours, more closely matching the postprandial glucose excursion than older regular insulin.

Insulin dosing is individualized and requires frequent adjustment based on self-monitored or continuous glucose data, carbohydrate content of meals (insulin-to-carbohydrate ratios), correction factors for hyperglycemia, anticipated exercise, illness, and stress. Most adults require 0.4 to 0.7 units per kilogram per day total daily dose, with roughly half allocated to basal and half to bolus coverage, though this varies considerably between individuals.

Continuous subcutaneous insulin infusion via insulin pump therapy (CSII) offers physiological advantages over MDI by enabling programmable basal rate profiles that vary by time of day, eliminating the need for long-acting insulin injections, and providing precise micro-boluses. CSII is the preferred delivery method for individuals who cannot achieve glycemic targets on MDI, those with hypoglycemia unawareness, pregnant women with T1DM, and patients who prefer the flexibility of a pump lifestyle. Modern tubeless patch pumps have enhanced comfort and discretion.

Continuous glucose monitoring is now recommended as standard of care for virtually all individuals with T1DM by the ADA and other major diabetes organizations. CGM devices measure interstitial glucose every 1 to 5 minutes and provide real-time values, trend arrows indicating the direction and rate of glucose change, and customizable alerts for impending hypoglycemia or hyperglycemia. Clinical evidence consistently demonstrates that CGM use reduces HbA1c, reduces time in hypoglycemia, increases time-in-range (percentage of time glucose is between 70 and 180 mg/dL), and improves quality of life compared to finger-stick monitoring alone.

Automated insulin delivery systems, sometimes called closed-loop or artificial pancreas systems, represent the most advanced treatment modality currently available. These systems integrate CGM readings with pump insulin delivery via a proprietary control algorithm that adjusts basal insulin delivery in real time to keep glucose within a target range. First-generation hybrid closed-loop systems require manual bolusing at meal times but automate basal adjustment. Advanced hybrid closed-loop systems with improved meal detection and more aggressive correction have further improved outcomes. Multiple randomized trials and real-world studies confirm meaningful improvements in time-in-range and HbA1c with AID compared to MDI or even CGM-augmented pump therapy alone.

Adjunctive pharmacotherapy is available for select patients. Pramlintide, a synthetic amylin analog, is FDA-approved in adults with T1DM as an adjunct to mealtime insulin to reduce postprandial glucose excursions and modestly reduce weight. SGLT-2 inhibitors including sotagliflozin (approved in Europe and some other markets) can lower HbA1c and body weight but carry a clinically significant risk of euglycemic DKA in T1DM patients, requiring rigorous patient selection and education about ketone monitoring and insulin adjustment rules. Teplizumab (Tzield), an anti-CD3 monoclonal antibody, received FDA approval in 2022 as the first therapy proven to delay the onset of clinical T1DM in individuals with stage 2 preclinical disease, representing a landmark advance in disease-modifying therapy.

Nutrition therapy is integral to diabetes management. Carbohydrate counting is the primary meal planning strategy, enabling patients to match insulin dose to anticipated glucose load. Low-carbohydrate diets have gained interest for their potential to reduce glycemic variability, though they require careful insulin adjustment and close monitoring. Regular follow-up with a registered dietitian specializing in diabetes is strongly encouraged.

## Living With Type 1 Diabetes

Managing type 1 diabetes extends far beyond medication and technology into every dimension of daily life. Successful self-management requires a high level of health literacy, technical skill, psychological resilience, and continuous adaptation to the unpredictable fluctuations of the disease.

Diabetes self-management education and support (DSMES) is the foundation of effective self-care. Structured education programs teach patients and families how to monitor glucose, calculate and administer insulin doses, recognize and treat hypoglycemia and hyperglycemia, manage sick days, interpret CGM data, operate insulin delivery devices, and adapt management during exercise, travel, and illness. The ADA recommends DSMES at diagnosis, annually, at times of complicating factors, and during life transitions.

Hypoglycemia management deserves particular attention. Hypoglycemia (blood glucose below 70 mg/dL) is the most common acute complication of insulin therapy and can progress to severe hypoglycemia with loss of consciousness, seizure, or death if not promptly treated. The 15-15 rule — consuming 15 grams of fast-acting carbohydrates and rechecking glucose after 15 minutes — is the standard treatment for mild hypoglycemia. Glucagon preparations (intranasal glucagon or auto-injector devices) must be prescribed and readily accessible for management of severe hypoglycemia. Hypoglycemia unawareness, in which warning symptoms are blunted due to recurrent hypoglycemia, requires structured blood glucose awareness training and often necessitates CGM with low-glucose alert settings.

Physical activity is strongly encouraged for its cardiovascular, metabolic, and psychological benefits, but requires proactive planning to avoid exercise-induced hypoglycemia or hyperglycemia. Strategies include reducing basal insulin or suspending pump delivery before prolonged aerobic exercise, consuming extra carbohydrates, and monitoring glucose frequently before, during, and after activity. High-intensity exercise may cause transient glucose elevation and may require a small correction bolus afterward.

The psychological burden of T1DM is substantial and often underrecognized. Diabetes distress — the emotional burden related to the demands of living with a complex chronic disease — affects up to 40 percent of adults with T1DM and is associated with suboptimal glycemic control and reduced quality of life. Depression and anxiety are also disproportionately prevalent. Routine screening for psychosocial issues should be integrated into diabetes clinic visits, and referral to mental health professionals with diabetes expertise should be readily available. Peer support programs and diabetes community organizations can provide valuable emotional support and practical advice.

## Prognosis and Complications

The prognosis for individuals with type 1 diabetes has improved substantially over recent decades with advances in insulin formulations, monitoring technology, and multidisciplinary care, yet the disease continues to carry significant morbidity and excess mortality relative to the general population.

Glycemic control, measured by HbA1c and increasingly by time-in-range, is the primary determinant of long-term complication risk. The landmark Diabetes Control and Complications Trial (DCCT), conducted between 1983 and 1993, enrolled 1,441 individuals with T1DM and demonstrated conclusively that intensive insulin therapy targeting HbA1c below 7 percent reduced the risk of retinopathy by 76 percent, nephropathy by 50 percent, and neuropathy by 60 percent compared to conventional therapy targeting HbA1c around 9 percent. The follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study demonstrated that the benefits of intensive control persisted for decades after the original trial ended — a phenomenon called metabolic memory — and that intensive therapy also reduced cardiovascular events by 42 percent.

Despite these findings, population-level HbA1c remains suboptimal in many T1DM patients. The T1D Exchange Registry in the United States has reported that only 17 to 20 percent of adults achieve an HbA1c below 7 percent, with rates even lower among adolescents. The advent of CGM and AID systems is improving time-in-range metrics at a population level, offering new hope for translating the DCCT's lessons into clinical reality for more patients.

Microvascular complications — retinopathy, nephropathy, and neuropathy — remain the most common serious complications. Diabetic retinopathy affects approximately 40 percent of individuals with T1DM over their lifetime and is the leading cause of new blindness in working-age adults. Diabetic nephropathy affects 20 to 40 percent of patients and can progress to end-stage renal disease requiring dialysis or transplantation. Peripheral neuropathy affects up to 50 percent of individuals after 25 years of disease, contributing to foot ulceration and lower extremity amputation.

Cardiovascular disease is the leading cause of mortality in T1DM, with coronary artery disease risk approximately 10-fold higher in individuals with T1DM compared to age-matched controls without diabetes. Aggressive management of cardiovascular risk factors — including smoking cessation, blood pressure control (target below 130/80 mmHg), lipid-lowering therapy with statins, and aspirin use in appropriate patients — is essential alongside glycemic management.

Overall life expectancy in T1DM, while improving, remains 11 to 13 years shorter than in the general population in large population-based registry studies. However, individuals diagnosed in more recent decades and managed with modern intensive therapy may see substantially better life expectancy outcomes as these cohorts age. Remaining free of major complications by middle age is associated with near-normal life expectancy.

## Frequently Asked Questions

What is the difference between type 1 and type 2 diabetes?

Type 1 diabetes is an autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreas, leading to absolute insulin deficiency. People with T1DM produce little to no insulin and require lifelong insulin therapy to survive. Type 2 diabetes, in contrast, develops when the body becomes resistant to insulin and the pancreas cannot produce enough to compensate. T2DM is strongly associated with obesity, physical inactivity, and aging, and is often managed initially with lifestyle changes and oral medications before insulin is required. The two conditions have different genetic backgrounds, pathophysiology, and treatment approaches, though both result in elevated blood glucose levels and share many long-term complications.

Can type 1 diabetes be prevented?

Currently, type 1 diabetes cannot be fully prevented, but early intervention in high-risk individuals can delay its onset. The FDA approved teplizumab (Tzield) in 2022 as the first disease-modifying therapy shown to delay clinical T1DM by a median of approximately two years in individuals with stage 2 disease — positive autoantibodies plus abnormal glucose tolerance but no symptoms. Screening first-degree relatives of people with T1DM for islet autoantibodies can identify those at high risk. Ongoing clinical trials are investigating additional immunotherapies and beta cell protective strategies.

What is diabetic ketoacidosis and how serious is it?

Diabetic ketoacidosis (DKA) is a life-threatening acute complication of type 1 diabetes that occurs when insulin deficiency causes the body to break down fat at an accelerated rate, producing acidic ketone bodies. DKA is characterized by high blood glucose, metabolic acidosis, and elevated ketones. Symptoms include nausea, vomiting, abdominal pain, rapid breathing, fruity-smelling breath, and altered consciousness. DKA requires urgent hospital treatment and, without prompt intervention, can be fatal. It is the most common cause of death in young people with T1DM.

How do insulin pumps and continuous glucose monitors improve diabetes management?

Continuous glucose monitors measure interstitial glucose every few minutes, eliminating frequent finger-stick testing and providing real-time data on glucose trends and alerts. Insulin pumps deliver insulin continuously through a small catheter, allowing programmable basal rates and precise mealtime boluses. When integrated into automated insulin delivery systems, a built-in algorithm automatically adjusts insulin delivery based on real-time glucose values, reducing both hypoglycemia and hyperglycemia. Clinical trials demonstrate that AID systems can significantly improve time-in-range and reduce HbA1c.

What are the long-term complications of type 1 diabetes?

Long-term complications result from sustained hyperglycemia damaging blood vessels and nerves. Microvascular complications include diabetic retinopathy, diabetic nephropathy, and peripheral neuropathy. Macrovascular complications include coronary artery disease, stroke, and peripheral arterial disease. Intensive glycemic control, as demonstrated by the DCCT trial, dramatically reduces the incidence and progression of these complications.

Can adults develop type 1 diabetes?

Yes, type 1 diabetes can develop at any age. A variant called Latent Autoimmune Diabetes in Adults (LADA) represents slowly progressive autoimmune diabetes in which individuals may initially appear to respond to oral medications but gradually lose beta cell function and require insulin. Adults with LADA typically have positive islet autoantibodies and lower C-peptide levels, distinguishing them from true T2DM. Accurate classification is critical because LADA patients will need insulin therapy.

How does exercise affect blood sugar in type 1 diabetes?

Exercise has complex and variable effects on blood glucose in T1DM. Aerobic exercise generally lowers blood glucose through insulin-independent glucose uptake in muscles, risking hypoglycemia. High-intensity anaerobic exercise can raise glucose through counter-regulatory hormone release. Management strategies include reducing insulin doses, consuming extra carbohydrates before and during activity, and using CGM for real-time monitoring. Despite these challenges, regular physical activity is strongly encouraged for its cardiovascular, metabolic, and psychological benefits.

Is a cure for type 1 diabetes possible in the near future?

Research into a functional cure is advancing rapidly. Islet transplantation has demonstrated that restoring functional beta cells can achieve insulin independence in some recipients, though immunosuppression requirements limit broad applicability. Stem cell-derived beta cell therapies, including encapsulated or gene-edited cells designed to evade immune rejection, are in active clinical trials. Immunotherapy approaches such as teplizumab may eventually be combined with beta cell replacement for a complete cure. While a cure is not yet available, the pace of innovation suggests transformative therapies may emerge within the coming decade.

## Conclusion

Type 1 diabetes mellitus is a complex, lifelong autoimmune disease that demands rigorous daily self-management and sustained engagement with a multidisciplinary healthcare team. Decades of clinical research have established that intensive glycemic control, achievable today through basal-bolus insulin regimens, continuous glucose monitoring, and automated insulin delivery systems, dramatically reduces the risk of debilitating microvascular and macrovascular complications. The approval of teplizumab marks a pivotal moment in the disease's history, offering for the first time the ability to delay clinical onset in high-risk individuals and signaling a new era of disease-modifying and potentially curative therapies on the horizon.

Patients and families living with T1DM should work closely with endocrinologists, diabetes educators, registered dietitians, and mental health professionals to develop individualized management plans that account for glycemic goals, lifestyle preferences, and psychosocial needs. Annual screening for complications — including retinal examination, urine albumin-to-creatinine ratio, comprehensive foot evaluation, and thyroid function testing — is essential for early detection and intervention.

Anyone experiencing the classic symptoms of new-onset diabetes — excessive thirst, frequent urination, unexplained weight loss, or fatigue — should seek prompt medical evaluation. Early diagnosis and initiation of insulin therapy prevents the potentially fatal complication of diabetic ketoacidosis and sets the foundation for a lifetime of informed, empowered diabetes self-management.